These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
544 related articles for article (PubMed ID: 30080247)
1. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247 [TBL] [Abstract][Full Text] [Related]
2. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Abdallah AO; Mahmoudjafari Z; Ahmed N; Cui W; Shune L; McGuirk J; Mohan M; Mohyuddin GR; Afrough A; Alkharabsheh O; Atrash S Eur J Haematol; 2023 Jun; 110(6):626-632. PubMed ID: 36752328 [TBL] [Abstract][Full Text] [Related]
4. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479 [TBL] [Abstract][Full Text] [Related]
5. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745 [TBL] [Abstract][Full Text] [Related]
6. The real-world outcomes of multiple myeloma patients treated with daratumumab. Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Gjerdrum LMR; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Dokhi M; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ PLoS One; 2021; 16(10):e0258487. PubMed ID: 34644367 [TBL] [Abstract][Full Text] [Related]
7. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437 [TBL] [Abstract][Full Text] [Related]
8. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237 [TBL] [Abstract][Full Text] [Related]
9. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538 [TBL] [Abstract][Full Text] [Related]
11. [Management of multiple myeloma in the relapsed/refractory patient]. Tabayashi T Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851 [TBL] [Abstract][Full Text] [Related]
12. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864 [TBL] [Abstract][Full Text] [Related]
14. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience. Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629 [TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003). Jing H; Yang L; Qi J; Qiu L; Fu C; Li J; Yang M; Qi M; Fan N; Ji J; Lu J; Li Y; Jin J Ann Hematol; 2022 Dec; 101(12):2679-2690. PubMed ID: 36301338 [TBL] [Abstract][Full Text] [Related]